Home > Focus Areas > Obesity Connect > Post
  • Saved

Did you know? Obesity is a chronic, relapsing neurobiological disease driven by dysregulation of appetite-regulating hormones and energy homeostasis. GLP-1 receptor agonism reduces caloric intake centrally and slows gastric emptying. In the STEP 1 trial, once-weekly semaglutide achieved sustained weight reductions with many patients losing more than 15% of body weight, along with meaningful improvements in cardiometabolic risk factors.

How has your framing of obesity as a chronic disease changed how you discuss treatment goals with patients?

 NCCN Guidelines

How has your framing of obesity as a chronic disease changed how you discuss treatment goals with patients?

Profile Image
  • 5d
    the framing as chronic disease helps to frame treatment for a lifestyle and willpower issues to a genetic and metabolic condition that will require lifelong treatment. Also helps with selection of therapy especially the GLP1 options.
  • 1w
    Obesity is not necessarily a choice, people struggle their whole lives despite their best efforts. This is a chronic disease and the approach should be the same as it is for other chronic diseases, including education, prevention, and strategies to manage it.
  • 1w
    Basically letting them know that this is not a personal failure or issue with will power but an actual medical condition (disease) that should and can be treated. That re-assurance alone will help the entire process of treating the disorder and the trust between patient and clinician. Also since again this is a chronic condition than the treatment is also. No quick fixes! Even GLP1 have their limitations and if all things aren't considered then once the medication is stopped the weight creeps back on.
  • 1w
    I advise lifestyle modifications along with GLP1s for weight loss in appropriate patient. There is no magic wand that I can wave in the air to help the patients lose weight, they have to do their part to achieve the weight loss they desire
  • 1w
    usually we discuss how GLP-1 works and how it slows down the gut, decreases appetite, and the side effects of eating junk food or over eating can cause more issues
  • 2w
    GLP-1 receptor agonists mimic natural metabolic gut hormones. They slow down gastric emptying prolonging fullness after meal.

Show More Comments